Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | DHFR | P00374 | 6/20 | 0.51 |
| ▸ | HEXA | P06865 | 1/20 | 0.49 |
| ▸ | HEXB | P07686 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4354112 | 0.86 | FGFR1 (0.56) | FGFR1LCKKDRJAK3MAPK14 | |
| SCHEMBL8122405 | 0.84 | FGFR1 (0.76) | FGFR1LCKKDRJAK3MAPK14 | |
| SCHEMBL4200127 | 0.83 | FGFR1 (0.71) | FGFR1LCKKDRJAK3MAPK14 | |
| SCHEMBL27612441 | 0.79 | DHFR (0.55) | FGFR1LCKKDRJAK3MAPK14 | |
| SCHEMBL4188897 | 0.79 | DHFR (0.54) | FGFR1LCKKDRJAK3MAPK14 | |
| SCHEMBL4357670 | 0.79 | DHFR (0.50) | FGFR1LCKKDRJAK3MAPK14 | |
| SCHEMBL28330246 | 0.79 | P2RX3 (0.59) | DHFR | |
| SCHEMBL3425059 | 0.78 | ADORA2A (0.56) | FGFR1LCKKDRJAK3MAPK14 | |
| SCHEMBL4186547 | 0.78 | DHFR (0.56) | FGFR1DHFRSRCADORA2AADORA1 | |
| SCHEMBL4613355 | 0.78 | DHFR (0.51) | DHFRADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| EP-3562811-A1 | HETEROARYL COMPOUNDS AND THEIR USE | Minoryx Therapeutics S.L. (ES) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018122775-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2018-07-05 | — | — | WO | disclosed |
| EP-1951684-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | Targegen, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |